Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new biosimilars or generics in 2025, as featured in the latest edition of Fierce Pharma’s annual special report documenting the 10 biggest losses of U.S. exclusivity expected throughout the year.

In this week’s episode of The Top Line, we dig into the report, which details the stories behind 10 key medicines that are set to face off against new generic or biosimilar competitors this year as their patents expire. Fierce’s Eric Sagonowsky and Angus Liu recap the report, sharing their perspectives on several of the drugs and discussing the industry effects of 2025’s sizable patent cliff.

To learn more about the topics in this episode:

• The top 10 drugs losing US exclusivity in 2025 

• After patent settlement, Amgen scores FDA nod for its biosimilar version of J&J's Stelara 

• Amgen grabs FDA thumbs-up for Soliris biosim, eyes 2025 launch 

• Novartis wins 11th-hour bid to block generic version of blockbuster heart med Entresto 

• Amgen settles Prolia patent suit with Celltrion, teeing up potential biosimilar launch in June